Key facts
- It has raised $12.0M; the latest was Accelerator/Incubator in Aug 2024.
- Notable investors include Johnson & Johnson Innovation - JLABS, Hana Ventures, Invest Detroit Ventures, Colopl Next, Chonnam National University Technology Holding Company — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for CNCure biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for CNCure biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CNCure biotech
Operator of a biotechnology company intended to provide expertise in drug development and cancer therapeutics. The company's offerings comprise an innovative microbial platform for cancer therapy, molecular imaging spies for making informed decisions, and a radio-theranostics platform for simultaneous diagnosis and treatment of diseases, providing healthcare professionals with science and technology that can diagnose diseases early and treat them to improve health conditions.
- Sector
- Healthcare
- HQ
- Muangun, South Korea
- Founded
- 2019
- Employees
- 17
- Website
- cncure.co.kr/
- Ownership
- Privately Held (backing)
CNCure biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CNCure biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CNCure biotech in its N-PORT filings yet. We sweep new filings monthly.